StockData
LENZ Therapeutics, Inc. logo

LENZ Therapeutics, Inc. (LENZ) stock

LENZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/3055% below fair value
$3.21−0.29 (-8.29%)

Close on Nov 18, 2026Market cap $100.86MP/E –Yield –

LENZ Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

LENZ Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$135.66M. For fiscal 2025 it was -$91.14M. The highest annual figure on record is -$13.50M in fiscal 2020.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$91.14M–
FY2024Dec 31, 2024-$58.61M–
FY2023Dec 31, 2023-$72.43M–
FY2022Dec 31, 2022-$105.64M–
FY2021Dec 31, 2021-$60.44M–
FY2020Dec 31, 2020-$13.50M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$34.17M–
Q1 FY2026Mar 31, 2026-$44.14M–
Q4 FY2025Dec 31, 2025-$38.46M–
Q3 FY2025Sep 30, 2025-$18.89M–
Q2 FY2025Jun 30, 2025-$16.86M–
Q1 FY2025Mar 31, 2025-$16.93M–
Q4 FY2024Dec 31, 2024-$15.23M–
Q3 FY2024Sep 30, 2024-$12.95M–
Q2 FY2024Jun 30, 2024-$14.35M–
Q1 FY2024Mar 31, 2024-$16.09M–
Q4 FY2023Dec 31, 2023-$24.99M–
Q3 FY2023Sep 30, 2023-$19.87M–
Q2 FY2023Jun 30, 2023-$14.96M–
Q1 FY2023Mar 31, 2023-$12.62M–
Q4 FY2022Dec 31, 2022-$26.75M–
Q3 FY2022Sep 30, 2022-$26.15M–
Q2 FY2022Jun 30, 2022-$26.78M–
Q1 FY2022Mar 31, 2022-$25.96M–
Q4 FY2021Dec 31, 2021-$18.94M–
Q3 FY2021Sep 30, 2021-$14.60M–
Q2 FY2021Jun 30, 2021-$17.53M–
Q1 FY2021Mar 31, 2021-$9.37M–
Q4 FY2020Dec 31, 2020-$8.32M–
Q3 FY2020Sep 30, 2020-$3.76M–
Q2 FY2020Jun 30, 2020-$1.29M–

More LENZ Therapeutics figures

See a number that looks wrong?